Canada Approves First Semaglutide Generic: Lessons from the “Ozempic Case” for Patent Portfolio Management
On 28 April 2026, Health Canada (the federal agency responsible for the regulation of pharmaceuticals and healthcare products in Canada) granted Dr. Reddy’s Laboratories authorization for the first generic injectable semaglutide product on the Canadian market.


